These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 22687985)

  • 41. Acute inhibition of the Na(+)/Ca(2+) exchanger reduces proarrhythmia in an experimental model of chronic heart failure.
    Milberg P; Pott C; Frommeyer G; Fink M; Ruhe M; Matsuda T; Baba A; Klocke R; Quang TH; Nikol S; Stypmann J; Osada N; Müller FU; Breithardt G; Noble D; Eckardt L
    Heart Rhythm; 2012 Apr; 9(4):570-8. PubMed ID: 22075452
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Myocardial gene transfer and overexpression of beta2-adrenergic receptors potentiates the functional recovery of unloaded failing hearts.
    Tevaearai HT; Eckhart AD; Walton GB; Keys JR; Wilson K; Koch WJ
    Circulation; 2002 Jul; 106(1):124-9. PubMed ID: 12093781
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation.
    Lu HR; Vlaminckx E; Van de Water A; Rohrbacher J; Hermans A; Gallacher DJ
    Eur J Pharmacol; 2007 Dec; 577(1-3):222-32. PubMed ID: 18074444
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation.
    Lu HR; Vlaminckx E; Van de Water A; Rohrbacher J; Hermans A; Gallacher DJ
    Eur J Pharmacol; 2006 Dec; 553(1-3):229-39. PubMed ID: 17054943
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Role of the rabbit whole-heart model for electrophysiologic safety pharmacology of non-cardiovascular drugs.
    Ellermann C; Wolfes J; Eckardt L; Frommeyer G
    Europace; 2021 Jun; 23(6):828-836. PubMed ID: 33200170
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antiarrhythmic properties of a rapid delayed-rectifier current activator in rabbit models of acquired long QT syndrome.
    Diness TG; Yeh YH; Qi XY; Chartier D; Tsuji Y; Hansen RS; Olesen SP; Grunnet M; Nattel S
    Cardiovasc Res; 2008 Jul; 79(1):61-9. PubMed ID: 18367457
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Resistance of the failing dystrophic hamster heart to the cardioprotective effects of diltiazem and clentiazem: evidence of coronary vascular dysfunctions.
    Tanguay M; Jasmin G; Blaise G; Dumont L
    Can J Physiol Pharmacol; 1995 Aug; 73(8):1108-17. PubMed ID: 8564877
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Specific IK1 blockade: a new antiarrhythmic mechanism? Effect of RP58866 on ventricular arrhythmias in rat, rabbit, and primate.
    Rees SA; Curtis MJ
    Circulation; 1993 Jun; 87(6):1979-89. PubMed ID: 8504513
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarisations.
    Carlsson L; Abrahamsson C; Andersson B; Duker G; Schiller-Linhardt G
    Cardiovasc Res; 1993 Dec; 27(12):2186-93. PubMed ID: 8313427
    [TBL] [Abstract][Full Text] [Related]  

  • 50. QT prolongation in guinea pigs for preliminary screening of torsadogenicity of drugs and drug-candidates. II.
    Testai L; Breschi MC; Martinotti E; Calderone V
    J Appl Toxicol; 2007; 27(3):270-5. PubMed ID: 17265420
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Proarrhythmia as a class effect of quinolones: increased dispersion of repolarization and triangulation of action potential predict torsades de pointes.
    Milberg P; Hilker E; Ramtin S; Cakir Y; Stypmann J; Engelen MA; Mönnig G; Osada N; Breithardt G; Haverkamp W; Eckardt L
    J Cardiovasc Electrophysiol; 2007 Jun; 18(6):647-54. PubMed ID: 17388913
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Uni- or bi-ventricular hypertrophy and susceptibility to drug-induced torsades de pointes.
    Panyasing Y; Kijtawornrat A; Del Rio C; Carnes C; Hamlin RL
    J Pharmacol Toxicol Methods; 2010; 62(2):148-56. PubMed ID: 20435152
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Ventricular arrhythmias. A potential risk associated with the use of non-cardiovascular drugs prolonging the QT interval].
    Calderone V; Cavero I
    Minerva Med; 2002 Jun; 93(3):181-97. PubMed ID: 12094149
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Electrophysiologic and extracellular ionic changes during acute ischemia in failing and normal rabbit myocardium.
    Vermeulen JT; Tan HL; Rademaker H; Schumacher CA; Loh P; Opthof T; Coronel R; Janse MJ
    J Mol Cell Cardiol; 1996 Jan; 28(1):123-31. PubMed ID: 8745220
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Drug-related torsades de pointes in the isolated rabbit heart: comparison of clofilium, d,l-sotalol, and erythromycin.
    Eckardt L; Haverkamp W; Mertens H; Johna R; Clague JR; Borggrefe M; Breithardt G
    J Cardiovasc Pharmacol; 1998 Sep; 32(3):425-34. PubMed ID: 9733356
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dispersion of ventricular repolarization in left ventricular hypertrophy: influence of afterload and dofetilide.
    Gillis AM; Mathison HJ; Kulisz E; Lester WM
    J Cardiovasc Electrophysiol; 1998 Sep; 9(9):988-97. PubMed ID: 9786080
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Female gender is a risk factor for drug-induced long QT and cardiac arrhythmias in an in vivo rabbit model.
    Lu HR; Remeysen P; Somers K; Saels A; De Clerck F
    J Cardiovasc Electrophysiol; 2001 May; 12(5):538-45. PubMed ID: 11386514
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of epicardial or biventricular pacing to prolong QT interval and increase transmural dispersion of repolarization: does resynchronization therapy pose a risk for patients predisposed to long QT or torsade de pointes?
    Medina-Ravell VA; Lankipalli RS; Yan GX; Antzelevitch C; Medina-Malpica NA; Medina-Malpica OA; Droogan C; Kowey PR
    Circulation; 2003 Feb; 107(5):740-6. PubMed ID: 12578878
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Assessment of the proarrhythmic potential of the novel antiarrhythmic agent AZD7009 and dofetilide in experimental models of torsades de pointes.
    Wu Y; Carlsson L; Liu T; Kowey PR; Yan GX
    J Cardiovasc Electrophysiol; 2005 Aug; 16(8):898-904. PubMed ID: 16101634
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Potentially modifiable factors of dofetilide-associated risk of torsades de pointes among hospitalized patients with atrial fibrillation.
    Naksuk N; Sugrue AM; Padmanabhan D; Kella D; DeSimone CV; Kapa S; Asirvatham SJ; Lee HC; Ackerman MJ; Noseworthy PA
    J Interv Card Electrophysiol; 2019 Mar; 54(2):189-196. PubMed ID: 30353374
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.